The Asia Pacific Fusion Biopsy Market is expected to witness market growth of 12.9% CAGR during the forecast period (2020-2026).
Asia Pacific is expected to show fastest growth rate in the forecasted years. The rising awareness among urologists about the functions and features as well as sensitivity and specificity of the targeted MR/Ultrasound biopsy while performing a prostate biopsy is likely to drive the market. Furthermore, the growing private sector participation in healthcare mainly in countries like India, China, and Japan that own high purchasing capabilities are also anticipated to have a positive impact on the fusion biopsy market.
The major companies are emphasizing more on R&D to develop advancement in hardware and software solutions to rationalize the workflow of the targeted MRI/US fusion biopsy. The novel version had an additional accessory of software and hardware to perform a transperineal fusion biopsy. The market players are shifting their attention to various strategies like product launches, collaborations mergers, and acquisitions, strengthening distribution networks, and trying to enter untapped markets, particularly in the developing economies to reinforce their market presence.
Ambulatory care centers are likely to grow at a fast rate in the foreseeable period of time. The increasing occurrence of prostate cancer in rural areas where there is limited access to healthcare service is one of the factors estimated to drive the growth of the market of fusion biopsy. Furthermore, the highly portable and low-cost MRI has been introduced and is anticipated to improve the adoption rate of the targeted MR/Ultrasound biopsy even in the ambulatory care centers, therefore, likely to boost the growth of the overall market.
Based on End Use, the market is segmented into Diagnostic centers, Hospitals and Ambulatory care centers. Based on Route, the market is segmented into Transperineal and Transrectal. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Australia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Hitachi, Ltd., Baxter International, Inc. (MedCom), Esaote SpA, Eigen, KOELIS, Inc., Focal Healthcare, Inc. and UC-Care Medical Systems Ltd.
Scope of the Study
Market Segmentation:
By End Use
By Route
By Country
Companies Profiled
Unique Offerings from the Publisher
Asia Pacific is expected to show fastest growth rate in the forecasted years. The rising awareness among urologists about the functions and features as well as sensitivity and specificity of the targeted MR/Ultrasound biopsy while performing a prostate biopsy is likely to drive the market. Furthermore, the growing private sector participation in healthcare mainly in countries like India, China, and Japan that own high purchasing capabilities are also anticipated to have a positive impact on the fusion biopsy market.
The major companies are emphasizing more on R&D to develop advancement in hardware and software solutions to rationalize the workflow of the targeted MRI/US fusion biopsy. The novel version had an additional accessory of software and hardware to perform a transperineal fusion biopsy. The market players are shifting their attention to various strategies like product launches, collaborations mergers, and acquisitions, strengthening distribution networks, and trying to enter untapped markets, particularly in the developing economies to reinforce their market presence.
Ambulatory care centers are likely to grow at a fast rate in the foreseeable period of time. The increasing occurrence of prostate cancer in rural areas where there is limited access to healthcare service is one of the factors estimated to drive the growth of the market of fusion biopsy. Furthermore, the highly portable and low-cost MRI has been introduced and is anticipated to improve the adoption rate of the targeted MR/Ultrasound biopsy even in the ambulatory care centers, therefore, likely to boost the growth of the overall market.
Based on End Use, the market is segmented into Diagnostic centers, Hospitals and Ambulatory care centers. Based on Route, the market is segmented into Transperineal and Transrectal. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Australia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Hitachi, Ltd., Baxter International, Inc. (MedCom), Esaote SpA, Eigen, KOELIS, Inc., Focal Healthcare, Inc. and UC-Care Medical Systems Ltd.
Scope of the Study
Market Segmentation:
By End Use
- Diagnostic centers
- Hospitals
- Ambulatory care centers
By Route
- Transperineal
- Transrectal
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Australia
- Rest of Asia Pacific
Companies Profiled
- Koninklijke Philips N.V.
- Hitachi, Ltd.
- Baxter International, Inc. (MedCom)
- Esaote SpA
- Eigen
- KOELIS, Inc.
- Focal Healthcare, Inc.
- UC-Care Medical Systems Ltd.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Asia Pacific Fusion Biopsy Market by End Uses
Chapter 5. Asia Pacific Fusion Biopsy Market by Route
Chapter 6. Asia Pacific Fusion Biopsy Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Koninklijke Philips N.V.
- Hitachi, Ltd.
- Baxter International, Inc. (MedCom)
- Esaote SpA
- Eigen
- KOELIS, Inc.
- Focal Healthcare, Inc.
- UC-Care Medical Systems Ltd.
Methodology
LOADING...
